Identification of Biomarkers Associated with Lipid Metabolism in Lupus Nephritis (LN) and the Potential Therapeutic Efficacy of Alisol B 23 - acetate (ABA) for LN
Systemic lupus erythematosus (SLE) represents a complex autoimmune disorder, with lupus nephritis (LN) standing as one of its gravest complications. Dyslipidemia serves as a risk determinant for LN and is intricately linked to the disease activity of LN. Alisol B 23 - acetate exhibits potent anti - inflammatory, antioxidant, and lipid - metabolism - modulating capabilities. This research is dedicated to delving into the lipid - metabolism - related gene clusters in LN and constructing a predictive model. And endeavors to explore the potential therapeutic impact of ABA in ameliorating LN by regulating lipid metabolism.